WO1999029732A2
(en)
|
1997-12-08 |
1999-06-17 |
Lexigen Pharmaceuticals Corporation |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
|
US20030105294A1
(en)
*
|
1998-02-25 |
2003-06-05 |
Stephen Gillies |
Enhancing the circulating half life of antibody-based fusion proteins
|
DE69931908T2
(de)
*
|
1998-04-15 |
2007-01-11 |
Lexigen Pharmaceuticals Corp., Lexington |
Steigerung der antikörper-zytokin-fusionsproteinmediierten immunantwort durch mitverabreichung mit einem angiogeneseinhibitor
|
US7304150B1
(en)
*
|
1998-10-23 |
2007-12-04 |
Amgen Inc. |
Methods and compositions for the prevention and treatment of anemia
|
US7345019B1
(en)
*
|
1999-04-13 |
2008-03-18 |
The Kenneth S. Warren Institute, Inc. |
Modulation of excitable tissue function by peripherally administered erythropoietin
|
CZ299516B6
(cs)
*
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
US7067110B1
(en)
|
1999-07-21 |
2006-06-27 |
Emd Lexigen Research Center Corp. |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
EP1200479B1
(en)
*
|
1999-08-09 |
2006-02-01 |
Lexigen Pharmaceuticals Corp. |
Multiple cytokine-antibody complexes
|
US20050202538A1
(en)
*
|
1999-11-12 |
2005-09-15 |
Merck Patent Gmbh |
Fc-erythropoietin fusion protein with improved pharmacokinetics
|
WO2001058957A2
(en)
|
2000-02-11 |
2001-08-16 |
Lexigen Pharmaceuticals Corp. |
Enhancing the circulating half-life of antibody-based fusion proteins
|
US6586398B1
(en)
*
|
2000-04-07 |
2003-07-01 |
Amgen, Inc. |
Chemically modified novel erythropoietin stimulating protein compositions and methods
|
NZ522030A
(en)
*
|
2000-05-15 |
2004-11-26 |
F |
Erythropoietin composition with a multiple charged inorganic anion i.e. a sulfate a citrate or a phosphate to stabilize the composition
|
PL358582A1
(en)
*
|
2000-06-29 |
2004-08-09 |
Merck Patent Gmbh |
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
|
AU2001290312A1
(en)
*
|
2000-10-16 |
2002-04-29 |
Chugai Seiyaku Kabushiki Kaisha |
Peg-modified erythropoietin
|
MXPA03005406A
(es)
*
|
2000-12-20 |
2003-09-25 |
Hoffmann La Roche |
Conjugados de eritropoyetina.
|
WO2002049673A2
(en)
*
|
2000-12-20 |
2002-06-27 |
F. Hoffmann-La Roche Ag |
Conjugates of erythropoietin (pep) with polyethylene glycol (peg)
|
US20030072737A1
(en)
*
|
2000-12-29 |
2003-04-17 |
Michael Brines |
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
|
US7767643B2
(en)
|
2000-12-29 |
2010-08-03 |
The Kenneth S. Warren Institute, Inc. |
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
|
EP1234583A1
(en)
*
|
2001-02-23 |
2002-08-28 |
F. Hoffmann-La Roche Ag |
PEG-conjugates of HGF-NK4
|
AU2002248571B2
(en)
*
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
DE10112825A1
(de)
|
2001-03-16 |
2002-10-02 |
Fresenius Kabi De Gmbh |
HESylierung von Wirkstoffen in wässriger Lösung
|
WO2002079415A2
(en)
|
2001-03-30 |
2002-10-10 |
Lexigen Pharmaceuticals Corp. |
Reducing the immunogenicity of fusion proteins
|
EP1383785B1
(en)
*
|
2001-05-03 |
2011-03-16 |
Merck Patent GmbH |
Recombinant tumor specific antibody and use thereof
|
US6818613B2
(en)
|
2001-11-07 |
2004-11-16 |
Ortho-Mcneil Pharmaceutical, Inc. |
Aqueous sustained-release formulations of proteins
|
KR100467751B1
(ko)
|
2001-12-03 |
2005-01-24 |
씨제이 주식회사 |
생체내 에리스로포이에틴 활성이 증진된 융합단백질
|
AU2002357784B2
(en)
*
|
2001-12-04 |
2008-07-31 |
Merck Patent Gmbh |
Immunocytokines with modulated selectivity
|
WO2003049686A2
(en)
*
|
2001-12-06 |
2003-06-19 |
Fibrogen, Inc. |
Stabilization of hypoxia inducible factor (hif) alpha
|
DE10209822A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
|
DE10209821A1
(de)
|
2002-03-06 |
2003-09-25 |
Biotechnologie Ges Mittelhesse |
Kopplung von Proteinen an ein modifiziertes Polysaccharid
|
US7129267B2
(en)
|
2002-03-11 |
2006-10-31 |
Janssen Pharmaceutica N.V. |
Methods for SHP1 mediated neuroprotection
|
KR20060019501A
(ko)
*
|
2002-07-01 |
2006-03-03 |
더 케네쓰 에스. 워렌 인스티튜트 인코포레이티드 |
응답 세포, 조직 및 기관을 보호, 회복 및 향상시키기위한 재조합 조직 보호 사이토카인 및 이를 코딩하는 핵산
|
BR0313212A
(pt)
|
2002-07-24 |
2005-06-28 |
Hoffmann La Roche |
Aditivos de ácido de polialquileno glicol
|
US7459435B2
(en)
*
|
2002-08-29 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
ATE466085T1
(de)
*
|
2002-09-09 |
2010-05-15 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
US20050176627A1
(en)
*
|
2002-09-09 |
2005-08-11 |
Anthony Cerami |
Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin
|
PL375037A1
(en)
|
2002-09-11 |
2005-11-14 |
Fresenius Kabi Deutschland Gmbh |
Hydroxyalkyl starch derivatives
|
US7459436B2
(en)
*
|
2002-11-22 |
2008-12-02 |
Hoffmann-La Roche Inc. |
Treatment of disturbances of iron distribution
|
US7388079B2
(en)
*
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
KR101086660B1
(ko)
*
|
2002-12-17 |
2011-11-24 |
메르크 파텐트 게엠베하 |
Gd2 에 결합하는 마우스 14.18 항체의 인간화 항체(h14.18) 및 그것의 il-2 와의 융합
|
US7553930B2
(en)
|
2003-01-06 |
2009-06-30 |
Xencor, Inc. |
BAFF variants and methods thereof
|
US20060104968A1
(en)
|
2003-03-05 |
2006-05-18 |
Halozyme, Inc. |
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
|
AU2004227937B2
(en)
|
2003-03-31 |
2007-09-20 |
Xencor, Inc |
Methods for rational pegylation of proteins
|
US7610156B2
(en)
|
2003-03-31 |
2009-10-27 |
Xencor, Inc. |
Methods for rational pegylation of proteins
|
US7642340B2
(en)
|
2003-03-31 |
2010-01-05 |
Xencor, Inc. |
PEGylated TNF-α variant proteins
|
US7279174B2
(en)
*
|
2003-05-08 |
2007-10-09 |
Advanced Cardiovascular Systems, Inc. |
Stent coatings comprising hydrophilic additives
|
WO2004101600A2
(en)
*
|
2003-05-12 |
2004-11-25 |
Affymax, Inc. |
Novel poly(ethylene glycol) modified compounds and uses thereof
|
EP1625156B1
(en)
*
|
2003-05-12 |
2012-09-19 |
Affymax, Inc. |
Peptides that bind to the erythropoietin receptor
|
JP4266028B2
(ja)
*
|
2003-05-12 |
2009-05-20 |
アフィーマックス・インコーポレイテッド |
エリスロポエチン受容体に結合する新規ペプチド
|
EP2204193A3
(en)
*
|
2003-05-12 |
2010-08-18 |
Affymax, Inc. |
Novel spacer moiety for poly(ethylene glycol)-modified peptide-based compounds
|
CN1826131A
(zh)
*
|
2003-05-30 |
2006-08-30 |
森托科尔公司 |
利用转谷氨酰胺酶形成新的促红细胞生成素缀合物
|
US7662607B2
(en)
*
|
2003-07-30 |
2010-02-16 |
New Century Pharmaceuticals, Inc. |
Chalaropsis lysozyme protein and its method of use in anti-bacterial applications
|
WO2005014655A2
(en)
|
2003-08-08 |
2005-02-17 |
Fresenius Kabi Deutschland Gmbh |
Conjugates of hydroxyalkyl starch and a protein
|
EA010650B1
(ru)
*
|
2003-09-29 |
2008-10-30 |
Уоррен Фармасьютикалз, Инк. |
Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
|
WO2005035564A2
(en)
|
2003-10-10 |
2005-04-21 |
Xencor, Inc. |
Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
|
CN1901934B
(zh)
*
|
2003-12-19 |
2013-09-11 |
弗·哈夫曼-拉罗切有限公司 |
促红细胞生成素在治疗慢性炎症性肠病中铁分布紊乱中的用途
|
EP1548031A1
(en)
*
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Nature-identical erythropoietin
|
ES2387028T3
(es)
*
|
2003-12-31 |
2012-09-12 |
Merck Patent Gmbh |
Proteína de fusión de Fc-eritropoyetina con farmacocinética mejorada
|
CA2553528C
(en)
*
|
2004-01-21 |
2012-12-04 |
Nektar Therapeutics Al, Corporation |
Method of preparing propionic acid-terminated polymers
|
ZA200606224B
(en)
*
|
2004-02-02 |
2007-11-28 |
Ambrx Inc |
Modified human growth hormone polypeptides and their uses
|
EA010501B1
(ru)
|
2004-03-11 |
2008-10-30 |
Фрезениус Каби Дойчланд Гмбх |
Конъюгаты гидроксиалкилкрахмала и белка, полученные восстановительным аминированием
|
US7588745B2
(en)
*
|
2004-04-13 |
2009-09-15 |
Si Options, Llc |
Silicon-containing products
|
US7253650B2
(en)
|
2004-05-25 |
2007-08-07 |
International Business Machines Corporation |
Increase productivity at wafer test using probe retest data analysis
|
WO2006062685A2
(en)
*
|
2004-11-11 |
2006-06-15 |
Affymax, Inc. |
Novel peptides that bind to the erythropoietin receptor
|
KR20070108140A
(ko)
*
|
2004-11-11 |
2007-11-08 |
아피맥스, 인크. |
에리트로포이에틴 수용체에 결합하는 신규한 펩타이드
|
EP1841787A2
(en)
|
2005-01-25 |
2007-10-10 |
Cell Therapeutics, Inc. |
Conjugates of biologically active proteins having a modified in vivo half-life
|
EP1848461A2
(en)
*
|
2005-02-16 |
2007-10-31 |
Nektar Therapeutics Al, Corporation |
Conjugates of an epo moiety and a polymer
|
US7550433B2
(en)
|
2005-06-03 |
2009-06-23 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US8324159B2
(en)
*
|
2005-06-03 |
2012-12-04 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US7919461B2
(en)
|
2005-06-03 |
2011-04-05 |
Affymax, Inc. |
Erythropoietin receptor peptide formulations and uses
|
US20070072795A1
(en)
*
|
2005-09-28 |
2007-03-29 |
Anton Haselbeck |
Treatment of neurodegenerative disorders
|
PL1931704T3
(pl)
*
|
2005-10-04 |
2011-06-30 |
Zymogenetics L L C |
Wytwarzanie i oczyszczanie IL-29
|
US8124095B2
(en)
*
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
US8741260B2
(en)
*
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
US8053569B2
(en)
*
|
2005-10-07 |
2011-11-08 |
Armagen Technologies, Inc. |
Nucleic acids encoding and methods of producing fusion proteins
|
US20080171696A1
(en)
*
|
2005-10-21 |
2008-07-17 |
Avigenics, Inc. |
Pharmacodynamically enhanced therapeutic proteins
|
CN101291684A
(zh)
*
|
2005-10-21 |
2008-10-22 |
阿维季尼克斯股份有限公司 |
甘醇化和糖基化的禽类来源的治疗性蛋白
|
US8841255B2
(en)
|
2005-12-20 |
2014-09-23 |
Duke University |
Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
|
US20130172274A1
(en)
*
|
2005-12-20 |
2013-07-04 |
Duke University |
Methods and compositions for delivering active agents with enhanced pharmacological properties
|
DK1988910T3
(en)
*
|
2006-02-28 |
2018-01-22 |
Kodiak Sciences Inc |
ACRYLOYLOXYETHYLPHOSPHORYLCHOLINE-CONTAINING POLYMER CONJUGATES AND PREPARATION thereof
|
WO2007108505A1
(ja)
|
2006-03-22 |
2007-09-27 |
Chugai Seiyaku Kabushiki Kaisha |
エリスロポエチン溶液製剤
|
CN105820231A
(zh)
*
|
2006-08-04 |
2016-08-03 |
普罗龙药品有限责任公司 |
修饰型促红细胞生成素
|
US8497246B2
(en)
*
|
2006-08-18 |
2013-07-30 |
Armagen Technologies, Inc. |
Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
|
CN101678079B
(zh)
|
2006-11-28 |
2013-12-25 |
韩诺生物制约株式会社 |
修饰的促红细胞生成素多肽及其治疗用途
|
AR065083A1
(es)
*
|
2007-02-02 |
2009-05-13 |
Amgen Inc |
Hepcidina, antagonistas de la hepcidina y metodos de uso
|
US20090011040A1
(en)
*
|
2007-05-02 |
2009-01-08 |
Naash Muna I |
Use of compacted nucleic acid nanoparticles in non-viral treatments of ocular diseases
|
CL2008002053A1
(es)
*
|
2007-07-17 |
2009-05-22 |
Hoffmann La Roche |
Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
|
AR067536A1
(es)
*
|
2007-07-17 |
2009-10-14 |
Hoffmann La Roche |
Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
|
EP2182980A4
(en)
|
2007-07-27 |
2012-04-18 |
Armagen Technologies Inc |
METHOD AND COMPOSITIONS FOR INCREASED ALPHA IDURONIDASE ACTIVITY IN THE CNS
|
ES2750254T3
(es)
*
|
2007-09-27 |
2020-03-25 |
Amgen Inc |
Formulaciones farmacéuticas
|
US8796206B2
(en)
|
2007-11-15 |
2014-08-05 |
Amgen Inc. |
Aqueous formulation of erythropoiesis stimulating protein stabilised by antioxidants for parenteral administration
|
EP2235090B1
(en)
|
2008-01-11 |
2013-09-04 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
US8101706B2
(en)
|
2008-01-11 |
2012-01-24 |
Serina Therapeutics, Inc. |
Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
|
ES2500066T3
(es)
|
2008-01-25 |
2014-09-30 |
Amgen, Inc |
Anticuerpos frente a ferroportina y métodos de uso
|
CN101939443B
(zh)
|
2008-02-08 |
2014-01-29 |
Ambrx公司 |
经修饰瘦素多肽和其用途
|
TWI395593B
(zh)
|
2008-03-06 |
2013-05-11 |
Halozyme Inc |
可活化的基質降解酵素之活體內暫時性控制
|
KR20100135291A
(ko)
|
2008-04-14 |
2010-12-24 |
할로자임, 아이엔씨 |
히알루로난 관련 질환 및 상태 치료용 변형된 히알루로니다제 및 그 용도
|
AU2009246946B2
(en)
|
2008-05-01 |
2013-09-26 |
Amgen Inc. |
Anti-hepcidin antibodies and methods of use
|
EP4074327A1
(en)
|
2008-06-27 |
2022-10-19 |
Duke University |
Therapeutic agents comprising elastin-like peptides
|
PT2342223T
(pt)
|
2008-09-26 |
2017-07-07 |
Lilly Co Eli |
Polipéptidos de eritropoetina animal modificados e suas utilizações
|
ES2766257T3
(es)
|
2008-11-13 |
2020-06-12 |
Massachusetts Gen Hospital |
Métodos y composiciones para regular la homeostasis del hierro mediante la modulación de bmp-6
|
US8927249B2
(en)
|
2008-12-09 |
2015-01-06 |
Halozyme, Inc. |
Extended soluble PH20 polypeptides and uses thereof
|
EP2408474B1
(en)
|
2009-03-18 |
2019-06-26 |
Armagen, Inc. |
Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
|
CN102470286B
(zh)
|
2009-07-30 |
2015-02-25 |
霍夫曼-拉罗奇有限公司 |
移动式色谱柱隔板
|
WO2011024025A1
(en)
*
|
2009-08-28 |
2011-03-03 |
Avesthagen Limited |
An erythropoietin analogue and a method thereof
|
US9084743B2
(en)
|
2009-09-17 |
2015-07-21 |
Baxter International Inc. |
Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof
|
WO2011035914A1
(en)
*
|
2009-09-23 |
2011-03-31 |
Biogenerix Ag |
Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
|
HUE044865T2
(hu)
|
2009-10-09 |
2019-11-28 |
Armagen Inc |
Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
|
AU2010310457B2
(en)
|
2009-10-23 |
2015-07-02 |
Amgen Inc. |
Vial adapter and system
|
WO2011075185A1
(en)
|
2009-12-18 |
2011-06-23 |
Oligasis |
Targeted drug phosphorylcholine polymer conjugates
|
WO2011134979A2
(en)
*
|
2010-04-27 |
2011-11-03 |
Scil Technology Gmbh |
Stable mia/cd-rap formulation
|
BR112012031121B1
(pt)
|
2010-06-07 |
2022-09-27 |
Amgen Inc |
Dispositivo de distribuição de drogas, kit e método de operar um dispositivo de distribuição de droga utilizável
|
KR101809878B1
(ko)
|
2010-07-20 |
2017-12-15 |
할로자임, 아이엔씨 |
항-히알루로난제 투여와 관련된 유해 부작용의 치료
|
CA2808748C
(en)
|
2010-09-14 |
2018-09-11 |
Roberto Falkenstein |
Method for purifying pegylated erythropoietin
|
CA2824218C
(en)
|
2011-02-02 |
2019-12-03 |
Andreas Blaschyk |
Chromatography column support
|
WO2012109387A1
(en)
|
2011-02-08 |
2012-08-16 |
Halozyme, Inc. |
Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia
|
WO2012135315A1
(en)
|
2011-03-31 |
2012-10-04 |
Amgen Inc. |
Vial adapter and system
|
AU2012245231B2
(en)
|
2011-04-20 |
2016-10-13 |
Amgen Inc. |
Autoinjector apparatus
|
US9993529B2
(en)
|
2011-06-17 |
2018-06-12 |
Halozyme, Inc. |
Stable formulations of a hyaluronan-degrading enzyme
|
SI3045189T1
(en)
|
2011-10-14 |
2018-07-31 |
Amgen Inc. |
Injector and mode of composition
|
WO2013063155A2
(en)
|
2011-10-24 |
2013-05-02 |
Halozyme, Inc. |
Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof
|
EP2785378B1
(en)
|
2011-12-02 |
2020-05-13 |
Armagen, Inc. |
Methods and compositions for increasing arylsulfatase a activity in the cns
|
MX361727B
(es)
|
2011-12-30 |
2018-12-14 |
Halozyme Inc |
Variantes de polipeptido ph20, formulaciones y usos de las mismas.
|
AU2013243873B2
(en)
|
2012-04-04 |
2016-08-25 |
Halozyme, Inc. |
Combination therapy with an anti - hyaluronan agent and a tumor - targeted taxane
|
CN102816227A
(zh)
*
|
2012-08-30 |
2012-12-12 |
深圳赛保尔生物药业有限公司 |
回收促红细胞生成素的方法
|
WO2014062856A1
(en)
|
2012-10-16 |
2014-04-24 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
US20150290390A1
(en)
|
2012-11-21 |
2015-10-15 |
Amgen Inc. |
Drug delivery device
|
CN110041427B
(zh)
|
2013-03-15 |
2023-05-23 |
本质生命科学有限公司 |
抗铁调素抗体及其用途
|
TWI639453B
(zh)
|
2013-03-15 |
2018-11-01 |
美商安美基公司 |
用於注射器之匣盒
|
TWI580451B
(zh)
|
2013-03-15 |
2017-05-01 |
安美基公司 |
用於注射器之匣盒及使用具有自動注射器及匣盒之自動注射器設備之方法
|
WO2014149357A1
(en)
|
2013-03-22 |
2014-09-25 |
Amgen Inc. |
Injector and method of assembly
|
TW201534726A
(zh)
|
2013-07-03 |
2015-09-16 |
Halozyme Inc |
熱穩定ph20玻尿酸酶變異體及其用途
|
DK3041513T3
(da)
|
2013-09-08 |
2020-10-26 |
Kodiak Sciences Inc |
Zwitterioniske faktor viii-polymerkonjugater
|
EP3501575B1
(en)
|
2013-10-24 |
2021-12-01 |
Amgen Inc. |
Drug delivery system with temperature-sensitive-control
|
WO2015061386A1
(en)
|
2013-10-24 |
2015-04-30 |
Amgen Inc. |
Injector and method of assembly
|
US10994112B2
(en)
|
2014-02-05 |
2021-05-04 |
Amgen Inc. |
Drug delivery system with electromagnetic field generator
|
WO2015171777A1
(en)
|
2014-05-07 |
2015-11-12 |
Amgen Inc. |
Autoinjector with shock reducing elements
|
CA2948005C
(en)
|
2014-06-03 |
2023-07-18 |
Amgen Inc. |
Systems and methods for remotely processing data collected by a drug delivery device
|
US9840553B2
(en)
|
2014-06-28 |
2017-12-12 |
Kodiak Sciences Inc. |
Dual PDGF/VEGF antagonists
|
TR201907471T4
(tr)
|
2014-08-28 |
2019-06-21 |
Halozyme Inc |
Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
|
US10323088B2
(en)
|
2014-09-22 |
2019-06-18 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
ES2753391T3
(es)
|
2014-10-14 |
2020-04-08 |
Halozyme Inc |
Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas
|
WO2016061220A2
(en)
|
2014-10-14 |
2016-04-21 |
Amgen Inc. |
Drug injection device with visual and audio indicators
|
KR102210104B1
(ko)
|
2014-10-17 |
2021-02-01 |
코디악 사이언시스 인코포레이티드 |
부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
|
EP3689394A1
(en)
|
2014-12-19 |
2020-08-05 |
Amgen Inc. |
Drug delivery device with live button or user interface field
|
EP3233163B1
(en)
|
2014-12-19 |
2021-10-13 |
Amgen Inc. |
Drug delivery device with proximity sensor
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
EP3556411B1
(en)
|
2015-02-17 |
2021-06-30 |
Amgen Inc. |
Drug delivery device with vacuum assisted securement and/or feedback
|
US11806509B2
(en)
|
2015-02-27 |
2023-11-07 |
Amgen Inc. |
Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
|
WO2017039786A1
(en)
|
2015-09-02 |
2017-03-09 |
Amgen Inc. |
Syringe assembly adapter for a syringe
|
JP7082568B2
(ja)
|
2015-12-09 |
2022-06-08 |
アムジエン・インコーポレーテツド |
信号伝達キャップ付き自動注射器
|
AU2016381964B2
(en)
|
2015-12-30 |
2024-02-15 |
Kodiak Sciences Inc. |
Antibodies and conjugates thereof
|
WO2017120178A1
(en)
|
2016-01-06 |
2017-07-13 |
Amgen Inc. |
Auto-injector with signaling electronics
|
DK3429663T3
(da)
|
2016-03-15 |
2020-09-28 |
Amgen Inc |
Reduktion af sandsynligheden for glasbrud i anordninger til indgivelse af lægemidler
|
CN105820232B
(zh)
*
|
2016-04-08 |
2019-05-17 |
昂德生物药业有限公司 |
单修饰聚乙二醇重组人促红素的制备方法及其制品和应用
|
US11541168B2
(en)
|
2016-04-29 |
2023-01-03 |
Amgen Inc. |
Drug delivery device with messaging label
|
WO2017192287A1
(en)
|
2016-05-02 |
2017-11-09 |
Amgen Inc. |
Syringe adapter and guide for filling an on-body injector
|
EP3455142B1
(en)
|
2016-05-13 |
2023-08-09 |
Amgen Inc. |
Vial sleeve assembly
|
EP3458988B1
(en)
|
2016-05-16 |
2023-10-18 |
Amgen Inc. |
Data encryption in medical devices with limited computational capability
|
WO2017209899A1
(en)
|
2016-06-03 |
2017-12-07 |
Amgen Inc. |
Impact testing apparatuses and methods for drug delivery devices
|
WO2018004842A1
(en)
|
2016-07-01 |
2018-01-04 |
Amgen Inc. |
Drug delivery device having minimized risk of component fracture upon impact events
|
PL3484911T3
(pl)
|
2016-07-15 |
2021-03-08 |
F. Hoffmann-La Roche Ag |
Sposób oczyszczania PEGylowanej erytropoetyny
|
WO2018034784A1
(en)
|
2016-08-17 |
2018-02-22 |
Amgen Inc. |
Drug delivery device with placement detection
|
WO2018081234A1
(en)
|
2016-10-25 |
2018-05-03 |
Amgen Inc. |
On-body injector
|
WO2018136398A1
(en)
|
2017-01-17 |
2018-07-26 |
Amgen Inc. |
Injection devices and related methods of use and assembly
|
MX2019009625A
(es)
|
2017-02-17 |
2019-10-09 |
Amgen Inc |
Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
|
US11369736B2
(en)
|
2017-02-17 |
2022-06-28 |
Amgen Inc. |
Cannula insertion and retraction mechanisms
|
CA3050927A1
(en)
|
2017-03-06 |
2018-09-13 |
Brian Stonecipher |
Drug delivery device with activation prevention feature
|
MX2019010543A
(es)
|
2017-03-07 |
2019-10-21 |
Amgen Inc |
Insercion de agujas por sobrepresion.
|
KR20240005194A
(ko)
|
2017-03-09 |
2024-01-11 |
암겐 인코포레이티드 |
약물 전달 장치용 삽입 메커니즘
|
WO2018172219A1
(en)
|
2017-03-20 |
2018-09-27 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of an erythropoiesis stimulating protein
|
KR20240042212A
(ko)
|
2017-03-28 |
2024-04-01 |
암겐 인코포레이티드 |
플런저 로드 및 주사기 조립 시스템 및 방법
|
CA3061982A1
(en)
|
2017-06-08 |
2018-12-13 |
Amgen Inc. |
Syringe assembly for a drug delivery device and method of assembly
|
WO2018226565A1
(en)
|
2017-06-08 |
2018-12-13 |
Amgen Inc. |
Torque driven drug delivery device
|
MX2019015472A
(es)
|
2017-06-22 |
2020-02-19 |
Amgen Inc |
Reduccion del impacto/choque de la activacion del mecanismo.
|
MX2019015402A
(es)
|
2017-06-22 |
2020-07-20 |
Catalyst Biosciences Inc |
Polipeptidos de serina proteasa 1 de tipo membrana modificada (mtsp-1) y metodos de uso.
|
MX2019015479A
(es)
|
2017-06-23 |
2020-02-20 |
Amgen Inc |
Dispositivo electronico de administracion de farmacos con tapa accionada por un conjunto de conmutador.
|
JP7408398B2
(ja)
|
2017-07-14 |
2024-01-05 |
アムジエン・インコーポレーテツド |
二重ねじりばねシステムを有する針挿入後退システム
|
IL271173B2
(en)
|
2017-07-21 |
2024-04-01 |
Amgen Inc |
Gas permeable sealing element for drug container and methods of assembly
|
US11484648B2
(en)
|
2017-07-25 |
2022-11-01 |
Amgen Inc. |
Drug delivery device with container access system and related method of assembly
|
US11617837B2
(en)
|
2017-07-25 |
2023-04-04 |
Amgen Inc. |
Drug delivery device with gear module and related method of assembly
|
WO2019032482A2
(en)
|
2017-08-09 |
2019-02-14 |
Amgen Inc. |
HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
|
WO2019036181A1
(en)
|
2017-08-18 |
2019-02-21 |
Amgen Inc. |
BODY INJECTOR WITH STERILE ADHESIVE PATCH
|
US11103636B2
(en)
|
2017-08-22 |
2021-08-31 |
Amgen Inc. |
Needle insertion mechanism for drug delivery device
|
ES2939292T3
(es)
|
2017-10-04 |
2023-04-20 |
Amgen Inc |
Adaptador de flujo para dispositivo de administración de fármacos
|
CN111132711B
(zh)
|
2017-10-06 |
2022-07-01 |
安进公司 |
带有联锁组件的药物递送装置及相关组装方法
|
EP3694578A1
(en)
|
2017-10-09 |
2020-08-19 |
Amgen Inc. |
Drug delivery device with drive assembly and related method of assembly
|
WO2019090079A1
(en)
|
2017-11-03 |
2019-05-09 |
Amgen Inc. |
System and approaches for sterilizing a drug delivery device
|
AU2018358749B2
(en)
|
2017-11-06 |
2024-02-29 |
Amgen Inc. |
Drug delivery device with placement and flow sensing
|
EP3707075A1
(en)
|
2017-11-06 |
2020-09-16 |
Amgen Inc. |
Fill-finish assemblies and related methods
|
CA3079665A1
(en)
|
2017-11-10 |
2019-05-16 |
Amgen Inc. |
Plungers for drug delivery devices
|
CA3084486A1
(en)
|
2017-11-16 |
2019-05-23 |
Amgen Inc. |
Autoinjector with stall and end point detection
|
JP7370969B2
(ja)
|
2017-11-16 |
2023-10-30 |
アムジエン・インコーポレーテツド |
薬物送達デバイスの扉ラッチ機構
|
US11518781B2
(en)
|
2017-12-29 |
2022-12-06 |
Hoffmann-La Roche Inc. |
Process for providing PEGylated protein composition
|
JP7137625B2
(ja)
|
2017-12-29 |
2022-09-14 |
エフ.ホフマン-ラ ロシュ アーゲー |
Peg化タンパク質組成物を提供するための方法
|
SI3731873T1
(sl)
|
2017-12-29 |
2022-05-31 |
F. Hoffmann-La Roche Ag |
Postopek za zagotavljanje sestavka PEGiliranih beljakovin
|
US20190351031A1
(en)
|
2018-05-16 |
2019-11-21 |
Halozyme, Inc. |
Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20
|
US10835685B2
(en)
|
2018-05-30 |
2020-11-17 |
Amgen Inc. |
Thermal spring release mechanism for a drug delivery device
|
US11083840B2
(en)
|
2018-06-01 |
2021-08-10 |
Amgen Inc. |
Modular fluid path assemblies for drug delivery devices
|
US20210369982A1
(en)
|
2018-07-24 |
2021-12-02 |
Amgen Inc. |
Delivery devices for administering drugs
|
CN112351804A
(zh)
|
2018-07-24 |
2021-02-09 |
安进公司 |
用于施用药物的输送装置
|
WO2020023336A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with grip portion
|
WO2020023220A1
(en)
|
2018-07-24 |
2020-01-30 |
Amgen Inc. |
Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation
|
US20210228797A1
(en)
|
2018-07-31 |
2021-07-29 |
Amgen Inc. |
Fluid path assembly for a drug delivery device
|
EP3613486B1
(de)
*
|
2018-08-24 |
2020-10-07 |
UGA Biopharma GmbH |
Verfahren und anlage zur reinigung von epo und/oder einem epo-derivat
|
CA3106452A1
(en)
|
2018-09-24 |
2020-04-02 |
Amgen Inc. |
Interventional dosing systems and methods
|
AU2019350660A1
(en)
|
2018-09-28 |
2021-03-18 |
Amgen Inc. |
Muscle wire escapement activation assembly for a drug delivery device
|
CA3110529A1
(en)
|
2018-10-02 |
2020-04-09 |
Amgen Inc. |
Injection systems for drug delivery with internal force transmission
|
US20210338936A1
(en)
|
2018-10-05 |
2021-11-04 |
Amgen Inc. |
Drug delivery device having dose indicator
|
AU2019359801A1
(en)
|
2018-10-15 |
2021-03-18 |
Amgen Inc. |
Platform assembly process for drug delivery device
|
EA202191037A1
(ru)
|
2018-10-15 |
2021-08-05 |
Эмджен Инк. |
Устройство доставки лекарственного средства, имеющее демпферный механизм
|
MA54066A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament à rétraction d'aiguille partielle
|
MA54057A
(fr)
|
2018-11-01 |
2022-02-09 |
Amgen Inc |
Dispositifs d'administration de médicament à rétraction partielle d'élément d'administration de médicament
|
EP3873566A1
(en)
|
2018-11-01 |
2021-09-08 |
Amgen Inc. |
Drug delivery devices with partial drug delivery member retraction
|
US11613744B2
(en)
|
2018-12-28 |
2023-03-28 |
Vertex Pharmaceuticals Incorporated |
Modified urokinase-type plasminogen activator polypeptides and methods of use
|
WO2020219482A1
(en)
|
2019-04-24 |
2020-10-29 |
Amgen Inc. |
Syringe sterilization verification assemblies and methods
|
MX2022002149A
(es)
|
2019-08-23 |
2022-03-17 |
Amgen Inc |
Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados.
|
AU2020364071A1
(en)
|
2019-10-10 |
2022-05-26 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2022063082A1
(zh)
|
2020-09-22 |
2022-03-31 |
美国杰科实验室有限公司 |
一种糖基化修饰的促红细胞生成素及其应用
|
WO2022159414A1
(en)
|
2021-01-22 |
2022-07-28 |
University Of Rochester |
Erythropoietin for gastroinfestinal dysfunction
|
AU2022271741A1
(en)
|
2021-05-10 |
2023-11-23 |
Chiome Bioscience Inc. |
Purification method of antibody composition
|
WO2022246055A1
(en)
|
2021-05-21 |
2022-11-24 |
Amgen Inc. |
Method of optimizing a filling recipe for a drug container
|
WO2023209074A1
(en)
|
2022-04-28 |
2023-11-02 |
Institut National de la Santé et de la Recherche Médicale |
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
|
CN116492448A
(zh)
*
|
2023-04-12 |
2023-07-28 |
深圳赛保尔生物药业有限公司 |
负载peg-epo及间充质干细胞的组合物、药物及其制备方法
|